Target intelligence / Profile preview

Host gut mucosal immune interface (GMI)

Target
GMI
Molecular classification
Other
01

Overview

The host gut mucosal immune interface is a complex biological system comprising the intestinal epithelium, the overlying mucus layer, and the underlying gut-associated lymphoid tissue (GALT). Its primary biological function is to maintain intestinal homeostasis by facilitating a delicate balance between immune tolerance toward commensal microbiota and dietary antigens, and robust protective immunity against enteric pathogens (Mowat & Agace, 2014, Nature Reviews Immunology). This interface acts as a physical and chemical barrier, utilizing tight junctions and antimicrobial peptides to prevent the translocation of luminal contents into the systemic circulation (Turner, 2009, Nature Reviews Immunology). In disease states such as inflammatory bowel disease (IBD) or celiac disease, this interface becomes dysregulated, leading to chronic inflammation, increased permeability, and barrier breakdown (Okumura & Takeda, 2017, Nature Reviews Immunology). While not a single molecular target, it serves as the critical site of action for numerous therapeutic agents, including monoclonal antibodies that block leukocyte migration or neutralize inflammatory cytokines (Danese et al., 2015, Gut). Understanding the cellular and molecular interactions at this interface is essential for developing precision medicines that restore immune equilibrium without compromising systemic host defense.

Other names
Intestinal mucosal barrierGut-immune axisIntestinal immune interfaceGut-associated lymphoid tissue interface
02

Mechanism of action

Modulation of leukocyte trafficking, neutralization of pro-inflammatory cytokines, and maintenance of epithelial barrier integrity.

03

Biological functions

Immune responseBarrier functionHomeostasisAntigen presentationTolerance induction
04

Disease associations

Inflammatory bowel diseaseCeliac diseaseInfectionAllergyAutoimmunity
05

Safety considerations

Opportunistic infectionsMalignancy riskLoss of mucosal toleranceSystemic immunosuppression
06

Interacting drugs

Vedolizumab

5 more in the full profile.

07

Biomarkers

Fecal calprotectinC-reactive proteinSecretory IgACitrullineZonulin

Beyond the preview

Go deeper on Host gut mucosal immune interface (GMI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host gut mucosal immune interface (GMI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call